GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis

Abstract

Two doses of GBR 830 administered 4 weeks apart were well tolerated and induced significant progressive tissue and clinical changes until day 71 (42 days after the last dose), highlighting the potential of OX40 targeting in patients with AD.